Project Summary/Abstract
PTEN is highly associated with autism, macrocephaly, and congenital hydrocephalus, which are increasingly
prevalent neurodevelopmental disorders that present in early childhood. Currently, there are no treatments that
address the cause of these conditions, despite mounting genetic evidence through large scale whole exome
sequencing studies that mutations in specific genes, including PTEN, confer increased risk for these disorders.
While these studies produce compelling targets for investigation, the role of PTEN in neurodevelopmental disorders
remains poorly understood. We seek to understand how PTEN, through its role as a negative regulator of the
greater mTOR pathway, contributes to early neurodevelopment using CRISPR-Cas9 loss-of-function models
in zebrafish. We have generated zebrafish mutants with frameshift mutations in exon 5 of both pten alleles present
in the teleost duplicated genome: ptena (Δ10) and ptenb (Δ2). We first aim to characterize neurodevelopmental
abnormalities in these fish, which preliminary data indicates have significant differences in brain volume, brain
activity, brain ventricle size, and startle response. We will further explore the function of PTEN in regulating cell
proliferation, differentiation, and establishment of the excitatory and inhibitory circuits in the brain. Secondly, we aim
to use this model to provide a new and accessible tool for screening the PTEN variants identified in children with
neurodevelopmental disorders, by injecting embryos with human mRNA constructs at the 1-cell stage and
evaluating neurodevelopmental changes. Lastly, we will perform a high-throughput drug screen of mTOR pathway
inhibitors and additional compounds which oppose or match the behavioral changes observed in our mutant larvae.
This will identify new potential pharmacological candidates. Our preliminary data already shows partial phenotype
rescue upon treatment with mTORC1-inhibitor sirolimus. In summary, these loss of function lines demonstrate
PTEN plays a critical role in early vertebrate neurodevelopment. Furthermore, these models provide a new and
accessible tool for screening the PTEN variants identified in neurodevelopmental disorders as well as potential
pharmacological candidates.